-
Posted by
Two Blokes Apr 30 -
Filed in
Stock
-
1 view
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of 2024 acquisition of US biosimilar Cimerli\u00ae (ranibizumab) and 2024 divestment of China business ten largest-selling medicines grew by combined 4% and represented 33% of net sales Europe net sales grew by 7%[1].
